Van Huynh

Van Huynh

Auto-generated profile, based on publicly available information

Van Huynh

Hyundai Cancer Institute Children's Hospital of Orange County (CHOC) Orange California USA

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 August 2022 in Pediatric Blood & Cancer
Verified
Journal Article
Closed access
JWJames A. Whitlock
James A. Whitlock
JMJemily Malvar
Jemily Malvar
LDLuciano Dalla‐Pozza
Luciano Dalla‐Pozza
JGJohn M. Goldberg
John M. Goldberg
LSLewis B. Silverman
Lewis B. Silverman
LGLia Gore
Lia Gore

3 October 2017 in Pediatric Hematology and Oncology
Verified
Journal Article
Closed access
VHVan Huynh
Van Huynh
TLTheodore Laetsch
Theodore Laetsch
RSReuven J. Schore
Reuven J. Schore
PGPaul Gaynon
Paul Gaynon
MOMaureen M. O'Brien
Maureen M. O'Brien
Technologies for the detection of minimal residual disease (MRD) in leukemia and our understanding of the prognostic implications of MRD at different phases of treatment have significantly improved over the past decade. As a result, definitions of treatment failure based on bone marrow morphology by light microscopy are becoming increasingly inadequate for clinical care and trial design. In addition, novel therapies that may have increased efficacy and decreased toxicity in the setting of MRD compared to overt disease are changing clinical practice and challenging investigators to redefine treatment failure, the role of disease surveillance in remission, and clinical trial eligibility in the era of MRD.

18 March 2026 in Cancer Epidemiology, Biomarkers & Prevention
Verified
Journal Article
Closed access
PKPragati Kore
Pragati Kore
JGJennifer M. Geris
Jennifer M. Geris
MLMaria Leon-Camarena
Maria Leon-Camarena
MCMaria I. Castellanos
Maria I. Castellanos
OTOlga A. Taylor
Olga A. Taylor
KRKaren R. Rabin
Karen R. Rabin
Background: Pediatric acute lymphoblastic leukemia (ALL) is the most common cancer in children, and its incidence and outcomes vary by race and ethnicity. Methods: The Reducing Ethnic Disparities in Acute Leukemia (REDIAL) Consortium has assembled a cohort of patients <25 years at diagnosis to examine genetic and neighborhood-level factors influencing ALL. As the cohort is ongoing, for this report, we examined sociodemographic and cytogenetic factors that might be associated with ALL outcome disparities. Results: Among 2,512 patients diagnosed between 2005 and 2020, we observed distinct patterns of genetic ancestry and residential characteristics across self-reported race and ethnicity. Latino children, who comprised 55.3% of the cohort, had a mean Amerindigenous ancestry proportion of 50.9%, whereas non-Latino White children exhibited a predominantly European ancestry (mean = 78%). Neighborhood-level analysis revealed significant socioeconomic and geographic differences by race/ethnicity, with Latino children more frequently residing in Latino enclaves or economically disadvantaged neighborhoods. Cytogenetic profiling of 551 patients showed that favorable subtypes (double trisomies and ETV6::RUNX1) predominated overall, but ETV6::RUNX1 was significantly less common in Latino than in non-Latino White children; conversely, CRLF2 overexpression and immunoglobulin heavy chain (IGH) rearrangements were more frequent among Latino children. Conclusions: This first REDIAL cohort analysis reveals how genetic ancestry and neighborhood-level factors jointly shape the distribution of ALL cytogenetic subtypes, advancing our understanding of contributors to disparities in ALL outcomes. Impact: This analysis offers insights into factors underlying disparities in ALL outcomes that may be targeted for mitigation, ultimately guiding more equitable approaches to risk stratification and intervention.

19 June 2026
Verified
Other
Open access
PKPragati Kore
Pragati Kore
JGJennifer M. Geris
Jennifer M. Geris
MLMaria Leon-Camarena
Maria Leon-Camarena
MCMaria I. Castellanos
Maria I. Castellanos
OTOlga A. Taylor
Olga A. Taylor
KRKaren R. Rabin
Karen R. Rabin
Supplementary Table S3 shows mean genetic ancestry by self-reported race/ethnicity.

26 August 2026 in Cancer Medicine
Verified
Journal Article
Open access
EMEmily J. Mason
Emily J. Mason
JWJohn P. Woodhouse
John P. Woodhouse
JSJeremy Schraw
Jeremy Schraw
JYJoanna S. Yi
Joanna S. Yi
KRKaren R. Rabin
Karen R. Rabin
ABAustin Brown
Austin Brown
Background: Hepatotoxicity is a common treatment‐related complication in pediatric acute lymphoblastic leukemia (ALL). Excess adiposity at diagnosis has been identified as a risk factor, but the impact of weight change during therapy has not been examined. Methods: We included patients aged 2–20 years newly diagnosed with ALL between 2005 and 2021. Hepatotoxicity was defined as: (1) transaminitis (ALT/AST > 10× the upper limit of normal), or (2) conjugated hyperbilirubinemia (cbili; > 3.0 mg/dL during induction/> 2.0 mg/dL post‐induction). Youden's J was used to identify optimal BMI z‐score thresholds. Cox proportional hazards regression was used to assess associations between hepatotoxicity during treatment and diagnostic BMI and post‐induction hepatotoxicity and weight change during induction. Associations were adjusted for age, race, ethnicity, and treatment risk stratification. Patients were censored at qualifying event or 1200 days post‐diagnosis. Results: Among 1070 patients (median age 6 years), 45.8% developed transaminitis and 7.6% cbili. Optimal BMI z‐score cut points were −1.5 and 1.5 for transaminitis and 1.5 for cbili. A BMI z‐score ≤ −1.5 was associated with reduced transaminitis (HR = 0.58, 95% CI: 0.39–0.86; p = 0.006), while a z‐score ≥ 1.5 was associated with increased transaminitis (HR = 1.32, 95% CI: 1.06–1.65; p = 0.01). A BMI z‐score ≥ 1.5 was also associated with increased cbili (HR = 1.97, 95% CI: 1.23–3.18; p = 0.01). Weight change was not associated with transaminitis, but weight loss during induction was associated with an increase in hazard of post‐induction cbili (HR = 1.08, 95% CI: 1.04–1.11; p < 0.0001). Conclusion: Diagnostic BMI z‐score and weight loss during induction were associated with increased hepatotoxicity risk, highlighting potential targets for improved risk stratification and hepatoprotective interventions.

24 October 2026 in JNCI Cancer Spectrum
Verified
Journal Article
Open access
THThanh T. Hoang
Thanh T. Hoang
AHAmy Hughes
Amy Hughes
PSPagna Sok
Pagna Sok
OROmar Rosales
Omar Rosales
KLKathleen F Ludwig
Kathleen F Ludwig
HZHong Zhu
Hong Zhu
Background: In acute lymphoblastic leukemia (ALL), minimal residual disease (MRD) is an established biomarker of treatment response and strongly associated with poor outcomes. Among children with ALL, air pollution has been associated with lower survival but has not been evaluated with prognostic biomarkers such as end of induction (EOI) MRD. Methods: Using the Reducing Ethnic Disparities in Acute Leukemia (REDIAL) Consortium, we analyzed 2125 pediatric patients with ALL. Daily fine particulate matter (PM2.5) estimates were obtained from the Centers for Disease Control and Prevention and linked to patients’ residential and treatment center census tracts. Mean daily PM2.5 during induction was calculated using two definitions: (1) based solely on patients’ residential address, and (2) Days 1 to 7 based on the treatment center and Days 8 to EOI on patients’ residence. Patients were categorized in quartiles based on mean daily PM2.5. EOI MRD ≥0.1% or ≥0.01% was considered positive. Adjusted odds ratios (aORs) and 95% confidence intervals (CIs) were calculated using logistic regression. Results: In B-cell ALL (B-ALL), mean daily residential PM2.5 during induction was associated with positive EOI MRD in quartiles 2 (aOR: 1.56, 95% CI = 1.08 to 2.24) and 3 (aOR: 1.51, 95% CI = 1.05 to 2.17) but not quartile 4 (aOR: 1.19). The association across all 3 quartiles strengthened when restricted to National Cancer Institute (NCI) high-risk B-ALL (aOR range: 1.73-2.28). Conclusions: Residential PM2.5 was associated with positive EOI MRD in patients with NCI high-risk B-ALL. Our findings contribute to a growing body of evidence that environmental exposures are associated with inferior outcomes among children diagnosed with ALL.